Neovacs S.A EV / EBITDA
Cos'è EV / EBITDA di Neovacs S.A?
EV / EBITDA di Neovacs S.A. è 3.93
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA di aziende nel Health Care settore su EURONEXT rispetto a Neovacs S.A
Cosa fa Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aziende con ev / ebitda simili a Neovacs S.A
- JNBY Design ha EV / EBITDA di 3.92
- ICO ha EV / EBITDA di 3.93
- Hydratec Industries NV ha EV / EBITDA di 3.93
- Independence Contract Drilling Inc ha EV / EBITDA di 3.93
- Steel City Securities ha EV / EBITDA di 3.93
- Rio Tinto Plc ha EV / EBITDA di 3.93
- Neovacs S.A ha EV / EBITDA di 3.93
- Supremex ha EV / EBITDA di 3.93
- Arkema SA ha EV / EBITDA di 3.93
- Dlsi ha EV / EBITDA di 3.93
- Albert David ha EV / EBITDA di 3.94
- Sino-Life ha EV / EBITDA di 3.94
- Signet Jewelers Ltd ha EV / EBITDA di 3.94